Background HIV incidence among adolescents in southern Africa remains unacceptably
high. Pre-exposure prophylaxis (PrEP) is an effective HIV prevention intervention but there …

Introduction Adolescent girls and young women (AGYW) in Africa have high HIV incidence
despite scale‐up of HIV testing and HIV treatment. Placebo‐controlled trials of tenofovir …

Introduction Oral tenofovir disoproxil fumarate/emtricitabine pre‐exposure prophylaxis
(PrEP), introduced into South Africa (SA) in 2016, has increasingly become part of HIV …

Adolescents are a critical population that is disproportionately impacted by the HIV
epidemic. More than 2 million adolescents between the age group of 10 and 19 years are …

Background Half of new HIV acquisitions in Africa occur in adolescent girls and young
women. Pre-exposure prophylaxis (PrEP) with oral tenofovir disoproxil fumarate plus …

Background HIV remains a major public health issue, especially in Eastern and Southern
Africa. Pre-exposure prophylaxis is highly effective when adhered to, but its effectiveness is …

Introduction HIV incidence remains high among African adolescent girls and young women
(AGYW), who would benefit from pre‐exposure prophylaxis (PrEP). Strategies to increase …

Background There are few data available regarding the use of on-demand pre-exposure
prophylaxis (PrEP) for HIV prevention. We aimed to assess PrEP effectiveness, adherence …

Adolescents and young women, particularly in South Africa, are at increased risk of HIV
acquisition. To date, we have had limited primary prevention options to offer. Oral pre …

Background The first Southern African HIV Clinicians Society pre-exposure prophylaxis
(PrEP) guidelines were published in the Southern African Journal of HIV Medicine in 2012 …